Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11060114 | 1.00 | ALDH1A1 (0.60) | ALDH1A1CYP1A2CYP2C19HIF1ACYP3A4 | |
| SCHEMBL11059512 | 0.98 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2C19HIF1ACYP3A4 | |
| SCHEMBL11115807 | 0.84 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2C19HIF1ACYP3A4 | |
| SCHEMBL16838612 | 0.84 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2C19HIF1ACYP3A4 | |
| Hydrochloric Acid SCHEMBL809087 | 0.83 | ALDH1A1 (0.53) | ALDH1A1CYP1A2CYP2C19HIF1ACYP3A4 | |
| SCHEMBL11059544 | 0.82 | ALDH1A1 (0.56) | ALDH1A1CYP1A2CYP2C19HIF1ACYP3A4 | |
| SCHEMBL11654135 | 0.82 | CYP1A2 (0.64) | ALDH1A1CYP1A2CYP2C19HIF1ACYP3A4 | |
| SCHEMBL808952 | 0.82 | CYP2A6 (0.48) | ALDH1A1CYP1A2MAPTRAB9ANPC1 | |
| SCHEMBL11051187 | 0.82 | KMO (0.45) | ALDH1A1CYP1A2MAPTRAB9ANPC1 | |
| SCHEMBL11064003 | 0.81 | SNCA (0.60) | ALDH1A1CYP1A2MAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10159678-B2 | Methods to decrease susceptibility to asthmatic bronchoconstriction | CORNELL UNIVERSITY (US) | 2018-12-25 | — | — | US | claimed |
| EP-1355638-B1 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS INC (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1355638-A2 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | Magnesium Diagnostics, Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| US-6455734-B1 | ADMINISTERING PHENYLGLYCINAMIDE(N-2,4-DIAMYLPENTANOIC ACID AMIDE) AS HYPOTENSIVE AGENTS FOR PROPHYLAXIS OF INSULIN RESISTANCE, ECLAMPSIA AND SENSITIVITY TO BLOOD METAL CONCENTRATIONS | MAGNESIUM DIAGNOSTICS, INC. | 2002-09-24 | — | — | US | claimed |
| WO-2002011714-A2 | ANTAGONISTS OF THE MAGNESIUM BINDING DEFECT AS THERAPEUTIC AGENTS AND METHODS FOR TREATMENT OF ABNORMAL PHYSIOLOGICAL STATES | MAGNESIUM DIAGNOSTICS, INC. (US) | 2002-02-14 | — | — | WO | claimed |
| US-11988661-B2 | Rapid quantitative test to diagnose polycystic kidney disease | UMC UTRECHT HOLDING, B.V. (NL) | 2024-05-21 | — | — | US | disclosed |
| US-20210333266-A1 | RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING, B.V. (NL) | 2021-10-28 | — | — | US | disclosed |
| US-11035852-B2 | Identifying drug candidates for treating polycystic kidney disease using organoids generated from primary cells | UMC UTRECHT HOLDING, B.V. (NL) | 2021-06-15 | — | — | US | disclosed |
| CN-109232396-B | Amide pyridine derivative and application thereof | 聊城大学 | 2020-07-03 | — | — | CN | disclosed |
| CN-109232396-A | Amide pyridine derivatives and application thereof | 聊城大学 | 2019-01-18 | — | — | CN | disclosed |
| US-10159678-B2 | Methods to decrease susceptibility to asthmatic bronchoconstriction | CORNELL UNIVERSITY (US) | 2018-12-25 | — | — | US | disclosed |
| EP-3045912-B1 | A RAPID QUANTITATIVE ASSAY TO MEASURE CFTR FUNCTION IN A PRIMARY INTESTINAL CULTURE MODEL | UMC UTRECHT HOLDING BV (NL) | 2018-09-19 | — | — | EP | disclosed |
| EP-0848957-A1 | Fas LIGAND SOLUBILIZATION INHIBITOR | KANEBO LTD. (JP) | 1998-06-24 | — | — | EP | disclosed |
| WO-1997014685-A1 | PYRIMIDINE DERIVATIVES | GYÓGYSZERKUTATÓ INTÉZET KFT (HU) | 1997-04-24 | — | — | WO | disclosed |
| EP-0254578-B1 | ANTIBIOTIC INTERMEDIATES | ELI LILLY AND COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| US-4772694-A | Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates | ELI LILLY AND COMPANY (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0254578-A1 | Antibiotic intermediates | ELI LILLY AND COMPANY (US) | 1988-01-27 | — | — | EP | disclosed |
| US-4490370-A | BACTERICIDES | ELI LILLY AND COMPANY (US) | 1984-12-25 | — | — | US | disclosed |
| EP-0122155-A2 | Improvements in or relating to naphthylglycyl cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1984-10-17 | — | — | EP | disclosed |
| US-4474780-A | STABLE | ELI LILLY AND COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10159678-B2 | Methods to decrease susceptibility to asthmatic bronchoconstriction | SMPD3, SMPD2, SMPD1 | ALDH1A1 1906/4885CYP1A2 3422/4885CYP2C19 3599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.